Neisseria gonorrhoeae MtrCDE Efflux Pump During In Vivo Experimental Genital Tract Infection in Men and Mice Reveals the Presence of Within-Host Colonization Bottleneck

- 1 Andreea Waltmann¹, Jacqueline T. Balthazar², Afrin A. Begum³, Nancy Hua⁴, Ann E. Jerse³,
- 2 William M. Shafer^{2,5,6}, UNC-Global Clinical Trials Unit/DMID 09-0106 Study Team⁷, Marcia
- 3 M. Hobbs^{1,8}*, Joseph A. Duncan^{1,9,10}*
- 4
- 5 ¹ Division of Infectious Diseases, Department of Medicine, School of Medicine, University of North
- 6 Carolina, Chapel Hill, NC, United States
- ² Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia,
 United States
- ⁹ ³Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland,
- 10 United States
- 11 ⁴ The Emmes Corporation, Rockville, Maryland, United States
- ⁵ The Emory Antibiotic Resistance Center, Emory University School of Medicine, Atlanta, Georgia,
- 13 United States
- ⁶Laboratories of Bacterial Pathogenesis, Veterans Affairs Medical Center (Atlanta), Decatur, Georgia,
- 15 United States
- ⁷See Supplemental Acknowledgments for, UNC-Global Clinical Trials Unit/DMID 09-0106 Study
- 17 Team member details
- 18 ⁸Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill,
- 19 North Carolina, United States
- 20 ⁹Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC,
- 21 United States
- ¹⁰ Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC,
- 23 United States
- 24 * Co-senior authors contributed equally

Address correspondence to: Joseph A. Duncan, Division of Infectious Diseases (Campus Box 7030), 130 Mason Farm Road, Chapel Hill, NC, 27599-7030, USA.; Phone: 1 (919) 843-0715 Email: jaduncan@med.unc.edu

Conflict-of-interest statement

The authors have declared that no conflict of interest exists.

25 Abstract

- 26 The MtrCDE efflux pump of Neisseria gonorrhoeae exports a wide range of antimicrobial
- 27 compounds that the gonococcus encounters at mucosal surfaces during colonization and
- 28 infection. Here, we evaluate the role of this efflux pump system in strain FA1090 in human male
- 29 urethral infection with a Controlled Human Infection Model. Using the strategy of competitive
- 30 multi-strain infection with wild-type FA1090 and an isogenic mutant strain that does not contain
- a functional MtrCDE pump, we found that the presence of the efflux pump during human
- 32 experimental infection did not confer a competitive advantage. This finding is in contrast to
- 33 previous findings in female mice, which demonstrated that gonococci of strain FA19 lacking a
- 34 functional MtrCDE pump had a significantly reduced fitness compared to the wild type strain in
- 35 the lower genital tract of female mice. We conducted competitive infections in female mice with
- 36 FA19 and FA1090 strains, including mutants that do not assemble a functional Mtr efflux pump,
- demonstrating the fitness advantage provided byt the MtrCDE efflux pump during infection of
- 38 mice is strain dependent. Our data indicate that new gonorrhea treatment strategies targeting the
- 39 MtrCDE efflux pump functions may not be universally efficacious in naturally occurring
- 40 infections. Owing to the equal fitness of FA1090 strains in men, our experiments unexpectedly
- 41 demonstrated the likely presence of an early colonization bottleneck of *N. gonorrhoeae* in the
- 42 human male urethra.
- 43 TRIAL REGISTRATION. Clinicaltrials.gov NCT03840811.
- 44

45 Introduction

46

47 *Neisseria gonorrhoeae* is exquisitely adapted to humans, its only natural host. The gonococcus is

- 48 equipped with multiple mechanisms that allow it to quickly respond to host innate immune
- 49 responses. The multiple transferrable resistance (Mtr) phenotype was first identified in 1973 as
- 50 providing decreased susceptibility of gonococci to structurally diverse hydrophobic antibiotics,
- 51 detergents and dyes (1) and was postulated to be due to decreased permeability of the bacterial
- 52 outer membrane to these antimicrobials (2). Over two decades later it was shown that the
- 53 resistance phenotype was due to the relief of transcriptional repression of the *mtrCDE* –encoded
- 54 efflux pump operon. The MtrCDE efflux pump is a member of the resistance-nodulation-
- 55 division family possessed by many Gram-negative bacteria (3, 4). The MtrCDE pump is critical
- 56 to the ability of N. gonorrhoeae to export a wide range of substrates that bathe mucosal surfaces,
- 57 including host-derived antimicrobials (antimicrobial peptides, bile salts, progesterone, fatty 58
- acids, and cathelicidins, such as human LL-37 or its murine homologue CRAMP-38), and 59 antibiotics (3, 5-10). The Mtr system has also been associated with enhanced resistance to killing
- 60 by human neutrophils and neutrophil products (11).
- 61
- 62 The *mtrCDE* operon is transcriptionally regulated by *cis*- and *trans*-acting control processes (5,
- 63 12, 13). MtrD is the inner membrane component of the pump and is connected to MtrE in the
- 64 outer membrane through the periplasmic membrane fusion lipoprotein MtrC (4, 6, 10). Efflux is
- 65 dependent on energy supplied by the proton motive force transduced by MtrD (14, 15).
- 66 Expression of *mtrCDE* in wild type gonococci is subject to repression by MtrR (7, 16, 17) and, in
- 67 the presence of an inducer, activation by MtrA (17, 18). Loss-of-function *mtrD* mutations
- 68 significantly reduce the ability of gonococci to colonize the lower genital tract of female mice in
- 69 experimental infection (19). Higher levels of the pump, on the other hand, either through
- 70 induction by MtrA, or de-repression through either loss of MtrR or through mutations in the Mtr
- 71 DNA-binding region enhance resistance to antibiotics (8, 20-23), host-derived antimicrobials (8),
- 72 and *in vivo* fitness in the mouse infection model (24). In strains that overexpress the pump, loss 73
- of MtrCDE can increase antibiotic susceptibility in otherwise clinically-resistant gonococci (25),
- 74 including strain H041, which was isolated from the first reported extended-spectrum-
- 75 cephalosporin resistant case of gonorrhea (26). These findings support the idea that the MtrCDE
- 76 efflux pump is important during *in vivo* infection (8, 24).
- 77
- 78

79 We hypothesized that mutations that abrogate the expression of the Mtr efflux pump would 80 affect N. gonorrhoeae infectivity in experimentally infected human males. We and others have 81 developed a model of experimental human gonococcal infection (reviewed in (27, 28)), which 82 takes advantage of the self-limited nature of gonococcal urethral infection in men. Infection can 83 be initiated in male participants through intraurethral inoculation, and this model has proven to 84 be a safe and efficient means of studying human urethral gonococcal infection without 85 serious complications (27, 28). With this model and the strategy of competitive infections 86 initiated by a mixture of wild type strain FA1090 and an isogenic FA1090 mutant that lacks MtrD, we sought to measure the importance of the MtrCDE efflux pump on N. gonorrhoeae 87 88 during experimental urethral infection of human males.

90 **Results**

91

92 Infectivity and clinical courses of infection in non-competitive infections

93 The genotypes of inoculating strains are shown in Table 1. Results are summarized in Table 2.

94 The evaluable population included participants who received a dose of *N. gonorrhoeae* within 1

95 log of the intended dose of one million organisms [i.e. Log₁₀(5), below which the inoculum size

96 is considered low at approximately ID₅₀] and reached an objective study endpoint (urethral

97 discharge or day 5). Six male participants were inoculated with wild type FA1090 A26 alone and

98 included in downstream analyses. Of nine men inoculated with FA1090 $\Delta mtrD$ alone, two were

99 excluded: one volunteer received a low inoculum dose at approximately ID₅₀ [inoculum

100 size= $Log_{10}(5.0)$] and a second volunteer requested treatment without signs, symptoms, or

101 positive cultures on day 2 post inoculation. Among participants included in final analyses, there

were no significant differences between the two strains with respect to infectivity, inoculum size,pyuria on treatment day, and time to treatment (Table 2). Among evaluable and infected

104 volunteers, bacteriuria on treatment day did not differ significantly between the two strains

105 (Table 2), nor were they deemed to be clinically meaningful. These results indicate the MtrCDE

(Table 2), not were they deemed to be childrenty meaningful. These results indicate the MitCD

106 efflux pump is not required for urethral infection in experimentally infected men.

107 108

The MtrCDE efflux pump does not confer a fitness advantage during urethral infection of men experimentally infected with strain FA1090 of *N. gonorrhoeae*

111 To determine whether the FA1090 Mtr efflux pump confers a fitness advantage to *N*.

112 gonorrhoeae in the male urethra, we conducted competitive infections using mixed FA1090 and

113 FA1090 $\Delta mtrD$ inocula. Twelve participants in four cohorts were inoculated with strain mixtures.

114 The evaluable population for competitive index calculations included participants who received a

dose of *N. gonorrhoeae* within 1 Log_{10} of the intended dose (Log_{10} 6) and reached an objective

116 study endpoint (urethral discharge or day 5) for whom a competitive index (CI) could be

117 calculated. Ten participants were evaluable and included in competitive fitness evaluations

118 (Table 3). One volunteer was urine culture-negative on treatment day, and thus the CI could not

119 be calculated. A second volunteer did not comply with specimen collection requirements,

120 because of which the processed urines were not the first void of the day. Among evaluable

121 participants, infectivity and course of infection parameters were similar to those in non-

122 competitive infections (Table 3).

123

124 The proportion of each strain in the inoculum and in urine sediment collected from each

125 participant on treatment day was determined by sub-culturing up to 96 colonies from each

126 positive urine sediment culture and enumerating strain-specific colony-forming units (cfu)by

127 real-time colony PCR (Supplementary Table 2). To assess whether the fitness of the

128 FA1090 $\Delta mtrD$ mutant was different than that of wild type, the ratio of mutant cfu as identified

by colony real-time PCR was compared to wild-type cfu for up to 96 recovered colonies per

130 participant. Log₁₀(CI) of participants inoculated with a mixture of FA1090 and FA1090 $\Delta mtrD$

131 group were compared using a Wilcoxon one-sample signed rank test to a hypothetical median of

132 0. We observed equal outcomes favoring the mutant strain and the wild type strain and overall

133 there was not enough vidence to reject the null hypothesis (p=0.477, one-sample signed rank

test, Figure 1A). Thus, expression of the FA1090 Mtr efflux pump did not confer a competitive

135 advantage during experimental human urethral infection.

136 The *in vivo* fitness advantage of the Mtr efflux pump is strain dependent in female mice

- 137 Given that previous studies on FA19 *mtr* mutant strains in female mice showed that *mtrD* and
- 138 *mtrE* mutants were attenuated for murine vaginal infection, and that the Mtr pump is important
- 139 for *in vivo* survival, either through induction by MtrA, the activator of the pump expression, or
- de-repression through loss of MtrR, the repressor of pump expression (8, 19, 24), the results of
- 141 the human competitive infections with FA1090 and FA1090 $\Delta mtrD$ were unexpected. 142 Furthermore, when investigating the role of LptA in FA1090 strains, which also increases
- Furthermore, when investigating the role of LptA in FA1090 strains, which also increases
 gonococcal resistance to innate defenses such as cationic antimicrobial peptides, the two models
- 144 showed similar results (29). Experimental infection of female BALB/c mice has been used
- extensively to study *N. gonorrhoeae* pathogenesis (8, 19, 24, 30-37). To determine whether this
- 146 discrepancy reflected differences between model systems, between strains, or between mutant
- 147 generation methodologies, we conducted competitive infections in female mice with the
- 148 following strain mixtures of wild type and mutant: wild type FA1090 with FA1090 $\Delta mtrD$, wild
- 149 type FA19 with FA19 $\Delta mtrD$, and wild type FA19 with FA19mtrD::kan, which was tested
- 150 previously (19). For this study, groups of female BALB/c mice were vaginally inoculated with
- 151 mixtures containing similar numbers of wild type and mutant bacteria (total dose, Log₁₀ 5.8-6).
- 152 The number of colonies of each strain recovered from vaginal swabs was determined for up to
- 153 5 days after inoculation; strain determination for each cfu was done by real-time PCR for
- 154 competitive infections with FA1090 and FA1090 $\Delta mtrD$ and with FA19 and FA19 $\Delta mtrD$;
- 155 quantitative selective culture was used for FA19 and FA19*mtrD::kan* competitive infections.
- 156
- 157 Among the 11 mice competitively infected with FA1090 and FA1090 $\Delta mtrD$ (Supplementary
- 158 Table 3), we observed five outcomes that favored the wild type FA1090 and six outcomes that
- 159 favored FA1090 $\Delta mtrD$ (p=0.672 1-sided Fisher's exact, Figure 1B). There was no significant
- 160 departure from the null hypothesis as the Log10(CIs) were not from different from the
- 161 hypothetical median of 0 (p=0.943, Wilcoxon one-sample signed rank test). Results with
- 162 FA1090 strains were not different in the two model systems (p=0.441, Mann-Whitney rank sum
- 163 test), although more mice than men had mixed strain recovery on the final positive culture day
- 164 (mice: 6/11, 54.5%; men: 1/10, 10.0%, p=0.045 one-sided Fisher's exact).
- 165
- 166 Among the 7 mice infected with mixtures of FA19 and FA19 $\Delta mtrD$, all but one outcome favored
- 167 wild type FA19, with a significant difference from the hypothetical median of 0 (p=0.031,
- 168 Wilcoxon one-sample signed rank test, Figure 1B). The FA1090 and FA19 results were
- 169 significantly different in the mouse model (p=0.047, Mann-Whitney rank sum test). All
- 170 outcomes in the 6 mice competitively infected with FA19 and FA19*mtrD*::kan favored the wild
- 171 type, with no mixed strain recovery on final day of positive cultures (p=0.030, Wilcoxon one-
- sample signed rank test, Figure 1C) in line with previously published results (8, 19, 24).
- 173
- We conclude that the *in vivo* phenotype of the FA1090 mutant that does not produce the MtrCDE
- pump is the same in the male urethritis and female mouse models, but that an interesting strain
- 176 difference between FA1090 and FA19 mutants was detected in the mouse model.
- 177

178 Strain dynamics during human infection indicate the presence of a colonization bottleneck

- 179 Lack of a functional Mtr efflux pump did not alter the fitness of the isogenic mutant relative to
- 180 wild type FA1090. Thus, our strategy of competitive infection enabled the incidental observation
- 181 of a potential urethral colonization bottleneck. Competitive infections with strains of equal

182 fitness have been used to study bottlenecks in other infection models. A bottleneck refers to

barriers to colonization or infection that substantially reduce the original population size in an

184 inoculum, such that a lower number of surviving organisms establish colonization and replicate

185 in the host. Our findings indicate that such a bottleneck exists early in the course of gonococcal 186 infection.

187

188 Figure 2A depicts the theoretical outcomes of one individual infection initiated with a 50:50

189 mixture of two hypothetical strains under conditions of bottleneck and absent bottleneck. When a

190 bottleneck is not present, the strategy of competitive infections can have two outcomes: if both

191 strains have equal fitness, the bacteria recovered from the host after inoculation mirrors the

inoculum (outcome 1). If one of the strains has an advantage, the expectation is for that strain to

193 progressively take over the dominate over the gonococcal population over course of infection 194 (outcome 2). Under the scenario of a bottleneck, if the same strain is at a competitive advantage,

then it is expected to dominate from early until late infection (outcome 3). When neither has a

196 fitness advantage and a bottleneck is preset, both strains will have equal chance of passing

197 through the bottleneck and establishing an infection; therefore, in outcome 4, equal numbers of

198 competitive infections would be dominated by each strain.

199

Figure 2B describes the observed outcomes for urine culture positive days in each of the 10

201 evaluable human participants, who on average received 40:60 mixed inocula of FA1090 and

202 FA1090 Δ *mtrD*. In the majority of men (8/10, 80.0%, Figure 2B), the predominant FA1090 strain

203 on treatment day began dominating early in the infection (day 1 post-inoculation). In 2/10 men

204 (20.0%), the predominating FA1090 strain from treatment day was different than the strain

dominating the recovered *N. gonorrhoeae* cfu from day 1 post-inoculation. In all but one man

206 (9/10, 90.0%), the strain composition of the first void urine on the final study day was uniformly

dominated by either strain. Strain dynamics from urine culture positive days support the

208 gonococcal bottleneck hypothesis.

211 Discussion

212

213 In the female mouse model of gonorrhea, the MtrCDE efflux pump was found to be important to 214 in vivo infection with N. gonorrhoeae strain FA19 (8, 19, 24). We anticipated human competitive 215 infections with wild type FA1090 and an isogenic polar mutant of FA1090 that lacked a 216 functional MtrCDE efflux pump to yield similar results. Contrary to our hypothesis, the two 217 strains exhibited equal fitness. The previous investigations using the murine model were 218 conducted with wild type strain FA19 and FA19 mutants whose MtrCDE efflux pump was 219 rendered non-functional via insertional inactivation (8, 19, 24). Thus, the discrepancy between 220 human and mouse results could be a reflection of strain, model, or mutagenesis methodology 221 differences. To separate potential differences with respect to strain, we conducted competitive 222 infections in mice with both FA1090 and FA19 parent strains and corresponding mutants that 223 lacked a functional MtrCDE efflux pump due to clean deletions of the mtrD gene 224 (FA1090 Δ *mtrD* and FA19 Δ *mtrD*). The FA1090 strains used in mouse infections were the same 225 strains used in human infections. The outcomes of competitive infection with FA1090 strains did 226 not differ between two model systems, indicating that the Mtr pump is not required for 227 colonization of murine lower genital tracts or human male urethras. However, mouse competitive 228 infections with FA19 strains showed that FA19 wild type had significant competitive advantage 229 relative to FA19 Δ *mtrD*. This competitive advantage was maintained when tested against the 230 same insertionally inactivated *mtrD* mutant used in the previous report (19) Nevertheless, 231 differences between infection models and mutagenesis strategies were noted, namely the more 232 frequent recovery of both wild type and mutant strains from mice compared to men during 233 competitive infections with FA10190 strains, and from mice inoculated with wild type FA19 in 234 combination with FA19 $\Delta mtrD$ relative to mice inoculated with wild type FA19 and 235 FA19mtrD::kan. Overall, our findings indicate that the fitness advantage conferred by the 236 MtrCDE efflux pump in the murine infection model is strain-dependent. Two established lines 237 of evidence suggest that strain dependent differences in MtrCDE-mediated enhanced fitness may 238 also be present during human infection. First, FA1090 naturally expresses reduced levels of the 239 pump compared to other strains, including FA19, due to an 11 bp deletion in the coding region 240 of *mtrA* that results in loss of MtrA-mediated gene activation due to premature truncation of this 241 transcriptional activator (18, 23). Thus, the null mutation in the *mtrD* gene in FA1090 may not 242 result in a strong fitness phenotype compared to the parental FA1090 strain that already 243 expresses a low level of MtrCDE (i.e., low expression in the wild type vs. no expression in the 244 mutant). This is consistent with the observed equal fitness of the strains during human and mouse 245 competitive infections. Second, a recent compelling study that investigated the population 246 genomics of the *mtrCDE* operon and its regulatory genes *mtrA* and *mtrR* using almost 5,000 global N. gonorrhoeae genomes, found that loss-of-function mutations related to the expression 247 248 of the MtrCDE efflux pump are relatively common in nature (38). In this global meta-analysis 249 (38), 362/4842 isolates (7.48%) were found to not have an inducible MtrCDE efflux pump due to 250 mutations in *mtrA*, of which the vast majority (357/362, 98.6%) harbored the same 11-bp 251 deletion as FA1090 mtrA. FA1090 was originally isolated from the endocervix of a female with 252 probable disseminated gonococcal infection (39) and the global population genomics study 253 found that loss of function mutations were over-represented among genomes from cervical 254 isolates; 25 of 129 cervical isolates (19.4%) carried *mtrA* loss of function mutations compared to 255 61 out of 2,248 urethral isolates (2.71%) (38). This finding indicates that strains with low levels 256 of MtrCDE efflux pump expression colonize the genital tracts of both females and males. Thus,

it may be reasonable to conclude that the possibility of strain-dependent requirement of the

258 MtrCDE efflux pump is representative of other naturally occurring gonococcal strains with non-

259 inducible MtrCDE efflux pumps. Although the pump may not be required to establish infection

- 260 in humans, evolving evidence suggests that overproducers of the pump may be better positioned
- 261 for antimicrobial resistance, as position 823 in MtrD is predicted to be a site for binding
- antimicrobials (38, 40).
- 263

The equal fitness of FA1090 and FA1090 $\Delta mtrD$ in urethral infection observed using competitive infection enabled the identification of a within-host bottleneck during the gonococcal infection process. To our knowledge, this is the first demonstration that productive infection with *N*. *gonorrhoeae* is likely initiated by a restricted number of gonococci rather than through a uniform expansion of the initial mixed inoculum, though the concept of a gonococcal colonization bottleneck was previously proposed (27). Transmission or colonization bottlenecks are drastic reductions in population size followed by clonal expansion of the "founder" organisms that

- 271 initiate the productive infection. Bottlenecks have been observed in enteric and systemic
- 272 infections caused by pathogenic bacteria in humans (41-47). Among sexually-transmitted
- 273 infections, human immunodeficiency virus 1 (HIV-1) bottlenecks have been studied but to date
- no studies have demonstrated their presence in bacterial sexually transmitted infections (48-51).
- 275

We tracked the daily strain dynamics during human competitive infections from day 1 postinoculation until the day of clinical urethritis (Figure 2). We noted that the "winning" strain outcompeted the "losing" strain within the first 24h of inoculation in the majority of participants (8/10) and persisted as dominant strain until the final study day. However, both strains were recovered from 8/29 positive cultures of 4/10 volunteers, albeit at very different proportions. Interestingly, in 2 participants (302 and 313) in which both strains were recovered, the strain

dominance observed on the first day after inoculation reversed the following day. While the study was not designed *a priori* to study populaton bottlenecks during *in vivo N. gonorrhoeae*

infection, our findings allude to some possible bottleneck characteristics with respect to type

285 (selective or non-selective), size (how many organisms are able to breach the initial barrier?),

- and timing.
- 287

288 First, it is possible that the gonococcal bottleneck is non-selective and strains overcome the

bottleneck with equal probability, as observed in murine models of *Streptococcus pneumoniae*

290 infection (43, 53-56). Our imposed genetic diversity of two strains is insufficient to answer this

291 question with any certainty. A selective bottleneck has also been described using *in vitro*

selection with human serum and in baby rat models of infection with the only other pathogenic

- 293 neisserial species, Neisseria meningitidis which happens to share 80-90% of its genome with the
- 294 gonococcus (61). The study showed experimentally that even when controlling for inoculum size

a strongly selective bottleneck for survival of meningococci is generated by bactericidal antibody

- directed against the carbohydrate antigen produced by the phase variable enzyme LOS
- 297 glycosyltransferase G, lgtG (61). Meningococcal variants existing within a population that do not
- express *lgtG* survive when exposed to a bactericidal monoclonal antibody specific for the epitope, whereas isogenic "ON" variants are killed essentially selecting for minority *ltgG* "OFF"
- 300 variants. Similar dynamics were observed in an infant rat model given the monoclonal antibody,
- with ltgG "OFF" variants escaping into the bloodstream after intraperitoneal inoculation.
- 302 Interestingly, the same gene also exists in N. gonorrhoeae (LOS glycosyltransferase G, lgtG)

303 (62) and it too undergoes phase variation (63) and is the target of a monoclonal antibody with304 promising immunotherapeutic potential (64, 65).

305

306 While the exact gonococcal bottleneck size cannot be inferred from our data, the recovery of

307 both strains from the same urine specimen indicates that the bottleneck is wider than one single

- 308 cell. This would stand in contrast to bottlenecks for other human bacterial pathogens, which have 309 tight single-cell bottlenecks (43, 45, 66) or for HIV-1 in which 80% of HIV-1 heterosexual
- 310 transmission is initiated from a single HIV-1 genetic variant (48-51), reviewed in (47).
- 311

Finally, based on the data in the current study, the timing of the bottleneck may vary between individuals and/or there may be more than one sequential bottleneck in play over the first 48 hours after exposure to *N. gonorrhoeae*. The timing of urine sampling in our experiments (every likely too infrequent to precisely determine the timing of the bottleneck. However, previous studies on the kinetics of opacity protein selection and pilin antigenic variation during

317 experimental human infection with FA1090 support the idea that the infecting population

- 318 encounters strong selective forces early in the infection process (67-70). Opacity and pilin
- 319 proteins are known for their extensive phase and antigenic variation in *N. gonorrhoeae*. The
- 320 opacity and pilin protein repertoire relative to the inoculum among the gonococcal isolates
- 321 recovered from experimentally infected males (67-70) undergoes rapid shifts and becomes
- 322 progressively more complex as infection progresses (67-70), consistent with the idea that
- 323 gonococci breaching the initial barrier may encounter additional pressures (e.g., host immune
- responses). The phenomenon of increased phase variation as a strategy to overcome bottlenecks and regenerate population diversity has been previously described for other bacteria (71-75).
- Whole genome and transcriptome studies utilizing the daily gonococcal samples from the
- 327 experimentally infected males of the current study to investigate phase variation and
- 328 transcriptomic dynamics are an important extension of this reported study that are currently
- 329 being undertaken.
- 330

In addition to the inherent limitations in characterizing the gonococcal bottleneck described above, open questions also remain with respect to the *in vivo* requirement of the MtrCDE efflux

- pump in human urethral infection. FA19 strains have not been characterized as a human
- challenge strain, and thus human experimental infection with FA19 strains were not possible to
- formally evaluate that the requirement of the MtrCDE pump is strain dependent in the human
- 336 male urethra. It is possible that the MtrCDE pump simply does not provide an advantage in the
- 337 male urethra, but confers a selective advantage in other ecologic niches, like the mouse vagina
- and possibly some anatomic sites in humans. By culturing urine rather than specimens directly
- 339 sampled from the urethral mucosa, it is possible that the adherent infecting bacterial population 340 is different from the bacteria that are shed and carried out of the urethra by flowing urine.
- is different from the bacteria that are shed and carried out of the urethra by flowing urine.Finally, whether the data of the experimental infections in males is representative of female
- infection or of extragenital sites remains an open question. Due to the risk of ascending
- 343 gonococcal infection, experimental gonorrhea in females is not ethically acceptable. Controlled
- human infection models of the orpharynx and rectum do not exist yet.
- 345
- 346 Overall, our study has provided compelling information regarding the MtrCDE efflux pump, a
- 347 well-studied *N. gonorrhoeae* virulence factor, and the presence of a population restriction
- 348 bottleneck during *in vivo* human infection. By showing that a strain of *N. gonorrhoeae* is able to

349 initiate a productive infection in the human male urethra even when the pump is not functional

- 350 we have generated data that can inform future gonorrhea vaccine and drug development efforts
- 351 that target the function of the Mtr efflux pump. By showing for the first time for a bacterial
- 352 sexually-transmitted pathogen that a bottleneck exists during *in vivo* human urethral infection we 353 have pointed towards a gonococcal Achilles heel could be exploited for novel control strategies;
- 354 knowledge of which host pressures drive the restriction of the pathogen population may answer
- 355 important biological questions regarding gonococcal infection progression or reveal genes that
- 356 are essential to the survival of N. gonorrhoeae. For example, as many as a third of all exposed
- 357 individuals will not develop an infection and of the 66% of exposures that proceed to infection.
- 358 \sim 50% of female genital infections and \sim 20% of male genital infection remain asymptomatic
- 359 (data reviewed in (52)). The determinants of these phenomena are unknown and physiologic
- 360 bottlenecks could play a role. Thus, the implications of our findings could have the potential of
- 361 ushering in fresh lines of inquiry in our quest for new and effective anti-gonococcal strategies. 362 This is important because in the face of increasing gonorrhea incidence and N. gonorrhoeae's
- 363 superbug status, the need to contain the threat of untreatable gonorrhea has become paramount.
- 364

365 **Methods**

Strains 366

- 367 N. gonorrhoeae strains used in this study are listed in Table 1. N. gonorrhoeae FA1090 served as
- 368 the parent strain for the human challenge investigations, whereas wild type FA1090 and FA19
- 369 were the parent strains for the mouse challenge experiments. FA1090 is a porin serotype PIB-3,
- 370 streptomycin (Sm)-resistant strain that has been used extensively in experimental human
- 371 infection studies (27). FA19 has been used widely in mouse challenge studies, including studies
- 372 of the Mtr efflux pump. The FA1090 human challenge inoculum strain, including the FA1090 373
- A26 variant utilized in the current studies in men and mice is piliated and predominantly Opa-374
- negative. FA1090 $\Delta mtrD$ is an isogenic mutant of FA1090, generated according to procedures
- 375 described below. In addition to FA1090 A26 and FA1090 $\Delta mtrD$, three other FA19 strains were 376 used in mouse challenge experiments (FA19 wild type and two mutant strains lacking a
- 377 functional Mtr pump, namely FA19 Δ *mtrD*, and FA19 *mtrD*::*kan*).
- 378 379

380 Generation and characterization of the mutant strains

- 381 To delete the *mtrD* gene and generate FA1090 Δ *mtrD*, a single colony of the FA1090 A26 as the
- 382 starting material was used in a two-step transformation, as previously described (81) and used by
- 383 us to delete *lptA* in FA1090. The deletion was made without leaving behind a selectable marker
- 384 (Supplementary Figure 1). Briefly, a two-gene cassette containing both a selectable marker
- 385 (chloramphenicol acetyl transferase [CAT] conferring chloramphenicol [Cm] resistance) and a
- 386 counter selectable marker (*rpsL*, conferring streptomycin [Sm] susceptibility on the naturally
- 387 resistant FA1090) was cloned into the *mtrD* gene and used to replace the wild type gene on the
- 388 chromosome by allelic exchange. A second transformation replaced the cassette-containing
- 389 version of the gene with an unmarked deletion. Targeted PCR amplification of the *mtrD* locus
- 390 and whole-genome sequencing of the FA1090 $\Delta mtrD$ genome sequence confirmed deletion of the
- 391 gene in the mutant. FA19 $\Delta mtrD$ was generated in the same manner as FA1090 $\Delta mtrD$ (i.e.,
- 392 leaving behind a clean deletion without a selectable marker), whereas the FA19 mtrD::kan
- 393 mutant was constructed via an insertional mutation, leaving behind a kanamycin selectable
- 394 marker, as previously described (19). While the mutant strains express the other two components

of the Mtr efflux pump, the lack of *mtrD* expression leads to the inability to assemble the pump.

396 MtrD expression contributes to gonococcal resistance to cationic antimicrobial compounds such

as polymyxin B (PB). Compared to parental strain FA1090 A26 the *mtrD* deletion mutant was

four-fold more PB susceptible (MICs of 100 vs. 25 μ g/ml, respectively).

399 400

401 Human urethral experimental infections

402 Procedures for human male participant recruitment, informed consent, intraurethral inoculation,

403 an antibiotic treatment were as previously described (27, 28, 82, 83). Females are excluded from

404 these studies due to risks of ascending gonorrhea infection into the upper reproductive tract.

405 Between April 2017 and November 2018, separate cohorts of up to 4 participants were

406 inoculated with FA1090 A26 alone, FA1090 $\Delta mtrD$ alone, or with mixtures of FA1090 A26

407 combined with FA1090 $\Delta mtrD$ containing approximately one million organisms. Gonococci in

408 the inoculum suspensions were predominantly Opa-negative, piliated and expressed the same

409 PilE sequence as previously characterized FA1090 variants used in experimental human

410 infection studies(29, 68). For competitive infections in men, mixtures of wild type FA1090 A26

411 and FA1090 $\Delta mtrD$ were prepared ahead of time and stored at - $\leq 70^{\circ}$ C until use. Procedures

412 pertaining to inoculum preparation for single and mixed strain infections have been previously

413 described (27-30, 82).

414

415 Participants were observed for up to 5 days post-inoculation and received antibiotics as soon as

416 discharge developed or on the final day of study (day 5 post-inoculation, irrespective of whether

417 they were deemed to be infected or not). Antibiotic treatment was with cefixime (single 400 mg

418 oral dose) or ceftriaxone (single 250 mg dose delivered intramuscularly). Infection alone without

419 discharge did not trigger treatment. First-void urine specimens were obtained daily after

420 inoculation for up to five days and examined quantitatively for pyuria (white blood cells) and

421 gonococci (bacteriuria). Participants were considered to be infected if they had a positive urine

422 culture or positive swab culture, with or without symptoms (i.e., urethral discharge). Urine

sediment was cultured quantitatively on GC agar with 3 g vancomycin, 12.5 units nystatin, and 5

424 g trimethoprim lactate/ml, which permits the growth of FA1090 and FA1090 $\Delta mtrD$. Inocula

425 used in single and mixed strain human challenges were also plated quantitatively. Colonies were

426 enumerated for bacterial quantitation. Up to 96 colonies per volunteer per culture day and up to

427 96 colonies from mixed inocula were picked and stored in freezing medium until strain

428 determination by real-time PCR.

429

430 Murine competitive infections

431 Female BALB/c mice (6 to 8 weeks old) were treated with Premarin and antibiotics to increase

432 susceptibility to *N. gonorrhoeae* as described previously (19, 84). Mixtures of relevant strains

433 were prepared on challenge day, as previously described (19). Groups of mice were inoculated

434 vaginally with the following mixtures: FA1090 and FA1090 $\Delta mtrD$, FA19 and FA19 $\Delta mtrD$, or

435 FA19 and FA19 *mtrD::kan*. Vaginal swabs were collected every other day for 5 days starting on

436 day 1 post-inoculation and suspended in 100 μ l GC broth. For mixtures containing deletion

437 mutants, vaginal swab suspensions were quantitatively cultured for *N. gonorrhoeae* on GCB

438 plates with Sm (100 μg /ml) plus 10 μg PMB/ml. Up to 48 colonies per mouse per culture day

439 were picked and stored in freezing medium until shipment to UNC-CH for strain determination

440 by real-time PCR, as described below. For competitive infections with FA19 and

441 FA19 *mtrD::kan*, vaginal swab suspensions were cultured on GC agar with Sm (100 μ g/ml) for

total CFU counts (wild-type and mutant) and GC agar with Sm (100 μ g/ml) plus Km (50 μ g/ml)

- to determine mutant CFU counts.
- 444
- 445

446 Strain determination in human competitive infections that contained clean deletion 447 mutants

448 Up to 96 colonies per human male volunteer per culture day and up to 48 colonies per mouse per 449 culture day were individually tested for strain determination using a duplex Taqman real-time 450 PCR assay (Supplementary Figure 1). Frozen, viable material from each colony was sub-cultured 451 in sterile 96 well microtiter plates by adding gonococci to 75 μ L of sterile GC broth (with 452 supplements) using aseptic technique and a replica plater tool. Gonococci were expanded

- 453 overnight (18-24h) at 35-37°C in a humidified atmosphere containing 5-7% CO₂ in order to
- 454 generate enough bacterial material for DNA isolation and subsequent strain detection by real455 time PCR.
- 456

457 Bacterial lysates were generated according to established procedures (85). Resulting lysates were

used as DNA template in the real-time assay. In brief, each well containing bacterial material
 expanded from a single colony was placed in 75 μL of sterile lysis buffer containing 2 mM

459 expanded from a single colony was placed in 75 μL of sterile lysis buffer containing 2 mM
460 EDTA, 50 mM Tris Cl at pH 8.5, and 1% Triton X-100 (85). Cells were lysed in 96-well PCR

461 plates using a thermocycler under the following cycling conditions: 15 min at 94°C followed by

462 incubation for 5 min at 25°C. Control lysates from each individual strain were made and

- 463 included as controls on each assay plate.
- 464

465 The simultaneous and specific detection of wild type and mutant strains was possible for three 466 reasons (Supplementary Figure 1): 1) the wild type specific primers and probe were located 467 within the *mtrD* gene, which is deleted in the mutant strains, and produce a 164bp product (note: 468 the *mtrD* gene in FA1090 and FA19 have 100% genetic homology); 2) the primers and probe 469 targeting the mutant strain were designed in a gap PCR fashion, whereby the forward and reverse 470 primers flank the *mtrD* deletion and the probe spans either side of the deletion; only if a deletion 471 is present, can the real-time assay utilize these primers and probe to amplify and detect the HEX-472 labeled 221 bp product; and 3) the two probes were labeled with two different fluorophores with 473 non-overlapping emission spectra (wild type probe was labeled at the 5' end with the FAM 474 fluorophore, which has an emission spectrum of 510-530 nm; and mutant probe was labeled at 475 the 5' end with HEX fluorophore, which has an emission spectrum of 560-580 nm). Real-time 476 assays were run in 384 well plates with five positive and five negative controls on each plate 477 using a ViiA 7 Real-Time PCR System from Applied Biosystems and the following cycling 478 conditions: 1 cycle at 95°C for 3 min, followed by 40 cycles at each of 95°C for 15 sec and 58°C

479 for 45 seconds. Primer and probe sequences, and PCR recipes are provided in Supplementary

Table 3. Only wells which gave a positive amplification signal for one, but not both targets, wereincluded for enumeration and competitive index calculation.

- 481 482
- 483

484 **Competitive index calculations**

For experimental murine and human infections, results for infected individuals were expressed as a competitive index (CI) using the equation:

487

$$CI = \frac{mutant \ CFU \ (output) \ / \ wild-type \ CFU \ (output)]}{mutant \ CFU \ (input) \ / \ wild-type \ CFU \ (input)}$$

488 Where

- 489 Output refers to the number of wild type and mutant cfu enumerated from cultures of urine
- 490 sediment or from cultures of mouse vaginal swab suspension
- 491 Input refers to the number of cfu enumerated from culture of bacterial suspension used to
- 492 inoculate that particular cohort/group of men or mice.
- 493
- 494 For human and mouse competitive infections, the culture limit of detection was assigned as 1
- 495 cfu/output cfu (e.g., 1/96 or 1/48, respectively). The competitive index can be equal to 1 if there
- 496 is equal fitness between the two strain, greater than 1 (or greater than 0 when expressed on the
- 497 logarithmic scale) if the mutant is favored or less than 1 (or less than 0 when expressed on the
- 498 logarithmic scale) if the wild type is favored.499

500 Statistics

- 501 The evaluable population in non-competitive infections included participants who received a
- dose of *N. gonorrhoeae* within 1 Log_{10} of the intended dose and reached an objective study
- 503 endpoint (urethral discharge or day 5). The evaluable population in competitive infections
- 504 included participants who received a dose of *N. gonorrhoeae* within 1 Log₁₀ of the intended
- 505 dose, reached an objective study endpoint (urethral discharge or day 5) and had at least one
- 506 positive urine culture.
- 507
- 508 Differences between groups were evaluated by Mann-Whitney rank-sum tests, 1-sided Fisher
- 509 exact tests, or Kruskall-Wallis test, as appropriate. The CI of the mixed group was tested against
- 510 the null hypothesis that the median equal zero using the one-sample Wilcoxon sign rank test and
- 511 alpha of 0.05.
- 512

513 Study approvals

- 514 Written informed consent from each participant was obtained prior to conducting any study
- 515 activities. Experimental human infections were conducted between 2017-2019 in the Clinical and
- 516 Translational Research Center of the North Carolina Translational and Clinical Sciences Institute
- 517 at the University of North Carolina at Chapel Hill according to the guidelines of the U.S.
- 518 Department of Health and Human Services and the University's Institutional Review Board
- 519 under a protocol for use of an investigational new drug (IND) that was authorized by the U.S.
- 520 Food and Drug Administration.
- 521 All animal experiments were conducted at the Uniformed Services University of the Health
- 522 Sciences according to the guidelines of the Association for the Assessment and Accreditation of
- 523 Laboratory Animal Care under a protocol that was approved by the University's Institutional
- 524 Animal Care and Use Committee.

525 Author contributions

- 527 MMH and JAD designed the research study, revised the manuscript, and conducted the human
- 528 experimental infections in conjunction with the UNC-Global Clinical Trials Unit/DMID 09-0106
- 529 Study Team. AW performed microbiology assessments and drafted the manuscript. MMH and
- 530 AW conducted data analysis. NH performed statistical analysis. WMS and JTB generated the
- 531 mutant strains. AEJ, KLC, and AAB conducted all the animal challenge studies. WMS and AEJ
- 532 edited the manuscript.
- 533
- 534

535 Acknowledgments and Funding Information

- 536
- 537 We extend our gratitude to the study participants. James Anderson and Lorraine Balleta provided
- technical support for the microbiologic assessments. See Supplemental Acknowledgments for
- 539 UNC-Global Clinical Trials Unit/DMID 09-0106 Study Team member details. We are grateful to
- 540 Holly Baughman and Jill El-Khorazaty from Emmes for the input on the study. The authors and
- 541 study were supported by funding from the National Institutes of Health, National Center for
- 542 Advancing Translational Sciences, National Institute of Allergy and Infectious Diseases, and
- 543 National Institute of General Medical Sciences through Grant Award Numbers U01AI114378,
- 544 TL1TR002491, UL1TR001111, R01AI021150 and U19AI113170. W.M.S. is the recipient of a
- 545 Senior Research Career Scientist Award from the Department of Veterans Affairs Medical
- 546 Research Service.
- 547
- 548
- 549

Main Figures and Tables

Table 1. Bacterial strains used in this study

Strain	MtrD pump expression	Reference
FA1090 A26	Not inducible due to 11 bp	
	deletion in coding region	(39)
	of activator <i>mtrA</i>	
FA1090∆mtrD	None	This study
FA19	Inducible (wild type <i>mtrA</i>)	(86)
FA19∆ <i>mtrD</i>	None	This study
FA19 mtrD::kan	None	This study and (19)

558 <u>Table 2.</u> Clinical course parameters of non-competitive infections in men inoculated with *N*.

559 gonorrhoeae FA1090 or N. gonorrhoeae FA1090⊿mtrD

560

Participant	Strain	Inoculum size ^a	Infected?	Bacteriuria ^b	Pyuria ^c	Day of Treatment ^d
232		6.6	Y	6.4	6.7	3
241		6.8	Y	4.5	6.3	2
242	EA 1000	6.7	Y	6.3	7.0	3
243	FA1090	6.8	Y	5.5	7.1	3
251		5.9	Y	2.0	6.4	1
252		6	Y	6.0	6.9	4
<i>Summary</i> ^e		6.5 (6.0-6.9)	100% (54%, 100%)	4.8 (3.0-7.6)	6.7 (6.4-7.1)	3.0 (2-3)
216		5.8	Y	6.2	6.2	3
220	FA1090∆ mtrD	6.4	Y	3.2	6.8	1
222		6.7	Y	4.0	8.0	2
223		6.7	Y	6.0	8.0	3
271		6.0	Y	0.7	6.0	4
272		6.1	Ν	ND	6.0	5
273		6.1	Y	2.0	6.9	4
<i>Summary</i> ^e		6.2 (5.9-6.6)	86% (42%, 100%)	3.0 (1.2-7.0)	6.8 (6.1-7.6)	3.0 (2-4)
<i>p-value</i> ^g		0.39	0.54	0.23	0.77	0.50

561 Y=yes, N=no

562 ^aLog₁₀ CFU *N. gonorrhoeae* mixture delivered to intraurethrally

563 ^bLog₁₀ CFU *N. gonorrhoeae* recovered/mL urine sediment on day of treatment

⁵⁶⁴ ^cLog₁₀ wbc/mL urine sediment on day of treatment

^dDays from inoculation to antibiotic ^eSummary statistics refer to geometric means with 95%

566 confidence intervals shown in brackets, except for the infectivity summary, which denotes the

567 percentage of participants deemed to have been infected (with 95% confidence intervals), and

time to treatment, which denotes the median time from inoculation to treatment (with

569 interquartile range). P-values were generated using the two-sided two-sample Wilcoxon rank-

570 sum test, except for the infectivity comparison for which the one-sided Fisher's exact test was

- 571 used.
- 572
- 573
- 574

575 <u>Table 3.</u> Infectivity and course of infection parameters in men infected competitively with

576 FA1090+FA1090*AmtrD*, and comparisons to the same parameters from non-competitive

577 infections in men.

-			
5	7	8	

Participant	Strain	Inoculum size ^a	Infected?	Bacteriuria ^b	Pyuria ^c	Day of Treatment ^d
281		6.6	Y	2.9	7.1	2
291		5.8	Y	5.2	6.9	4
292		5.8	Y	5.0	6.5	4
300		6.5	Y	4.6	6.9	4
301	FA1090+	6.5	Y	5.1	6.5	3
302	$FA1090\Delta$ mtrD	6.6	Y	5.0	6.3	2
303	inti D	6.5	Y	5.0	6.6	4
311		6.5	Y	3.2	6.9	2
313		6.3	Y	3.5	6.8	4
314		6.4	Y	3.5	7.0	4
<i>Summary</i> ^e		6.3 (6.1-6.6)	100% (69%, 100%)	4.2 (3.6-4.9)	6.7 (6.6-6.9)	4 (2.0-4.0)
Summary	FA1090	6.5 (6.0-6.9)	100% (54%, 100%)	4.8 (3.0-7.6)	6.7 (6.4-7.1)	3.0 (2.0-3.0)
Summary	FA1090∆ <i>mtrD</i>	6.2 (5.9-6.6)	86% (42%, 100%)	3.0 (1.2-7.0)	6.8 (6.1-7.6)	3.0 (2.0-4.0)
p-value ^f		0.38	0.56	0.25	0.91	0.48

579 Y=yes, N=no

580 ^aLog₁₀ CFU *N. gonorrhoeae* mixture delivered intraurethrally

581 ^bLog₁₀ CFU *N. gonorrhoeae* recovered/mL urine sediment on day of treatment

582 ^cLog₁₀ wbc/mL urine sediment on day of treatment

^dDays from inoculation to antibiotic treatment

⁶Summary statistics refer to geometric means with 95% confidence intervals shown in brackets,

585 except for the infectivity summary, which denotes the percentage of participants deemed to have

586 been infected (with 95% confidence intervals) and time to treatment, which denotes median time

587 from inoculation to treatment (with interquartile range). P-values were generated using Kruskal-

588 Wallis tests, except for the infectivity comparison for which the Fisher's exact test was used.

- 590
- 591



592

593

594 **Figure 1.** Results of competitive infections in men (n=10) and female mice.

595 **A.** Ten men were competitively infected with mixtures of FA1090 and FA1090 $\Delta mtrD$. Competitive indices were calculated as cfu mut OUT/cfu wt OUT ÷ cfu mut IN/cfu wt 596 597 IN recovered from first-void urine of experimentally infected men. CIs are graphed on 598 the logarithmic scale. Thus, $Log_{10}CI$ greater than 0 indicated the mutant was favored and 599 Log₁₀CI less than 0 indicates that the wild type was favored. For men, the last day of 600 positive cultures was treatment day when clinical urethritis was detected and/or when antibiotic treatment was given. Horizontal bars are the median CI for each group. White 601 602 squares refer to men from whom only the wild type was recovered the day of treatment. 603 Grey squares denote men from whom a mix of the two strains was recovered. Black 604 squares denote men from whom only the mutant strain was recovered.

605**B.** Eleven mice were inoculated with mixtures of FA1090 and FA1090 $\Delta mtrD$ and 7 mice606with mixtures of FA19 and FA19 $\Delta mtrD$. CIs were calculated using the same formula as607for the men using the cfu counts from mouse vaginal swabs on the last day of positive608cultures. CIs are graphed on the logarithmic scale. Horizontal bars are the median CI for609each group. White squares refer to mice from whom only the wild type was recovered on610last day of positive cultures. Grey squares denote mice from whom a mix of the two

- 611 strains was recovered. Black squares denote mice from whom only the mutant strain was612 recovered.
- 613 **C.** Six mice were inoculated with mixtures of FA19 and FA19*mtrD::kan* and CIs calculated 614 using cfu counts from mouse vaginal swabs on the last day of positive cultures. CIs are
- 615 graphed on the logarithmic scale. Note the different y axis scale for panel C, imposed by
- 616 the lower limit of detection of quantitative selective culture on GC agar for the
- 617 FA19+FA19 mtrD::kan competitive infections.



- 618
- 619
- 620

621 Figure 2. Gonococcal population dynamics during the early course of infection.

622 A) Theoretical infection outcomes with respect to strain composition for infections initiated from

623 50:50 mixtures of two strains, shown in black and white, that differ in their competitive

advantage in scenarios of bottleneck present early in the infection or no bottleneck (adapted with

625 permission from (27). Each pie chart represents a gonococcal population containing predicted

626 proportions of the two theoretical strains. When the two strains have equal fitness and a

bottleneck is present early in the course of infection that results in a population size restriction,

628 we predict that equal numbers of outcomes favoring each strain will be observed.

B) Empirically observed outcomes in the current study for infections initiated with mixed

630 inocula. Two to four men were inoculated with the same inoculum preparation in each of the

631 four study cohorts. A total of 10 evaluable participants were available for final analysis (281,

632 291, 292, 300, 301, 302, 303, 311, 313, 314). The pie chart representing the average inoculum

- from the four cohorts refers to the mean strain composition of the four independent inocula and
- on average comprised of 60% mutant strain and 40% wild type. Each participant pie chart

- 635 represents the daily mixture of gonococcal strains recovered from the urine over the 1- to 5-day
- 636 period after inoculation. Last pie chart in the series for each participant refers to the study
- 637 treatment day when clinical urethritis was apparent and/or when antibiotic treatment was
- 638 administered.

639 **Bibliography**

- 640 1. Maness MJ, and Sparling PF. Multiple antibiotic resistance due to a single mutation in
 641 Neisseria gonorrhoeae. *J Infect Dis.* 1973;128(3):321-30.
- 642 2. Guymon LF, Walstad DL, and Sparling PF. Cell envelope alterations in antibiotic643 sensitive and-resistant strains of Neisseria gonorrhoeae. *J Bacteriol.* 1978;136(1):391644 401.
- 645 3. Shafer WM, Qu X, Waring AJ, et al. Modulation of Neisseria gonorrhoeae susceptibility
 646 to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division
 647 efflux pump family. *Proc Natl Acad Sci U S A*. 1998;95(4):1829-33.
- Hagman KE, Lucas CE, Balthazar JT, et al. The MtrD protein of Neisseria gonorrhoeae is
 a member of the resistance/nodulation/division protein family constituting part of an
 efflux system. *Microbiology (Reading)*. 1997;143 (Pt 7):2117-25.
- Lucas CE, Hagman KE, Levin JC, et al. Importance of lipooligosaccharide structure in
 determining gonococcal resistance to hydrophobic antimicrobial agents resulting from the
 mtr efflux system. *Mol Microbiol*. 1995;16(5):1001-9.
- 654 6. Hagman KE, Pan W, Spratt BG, et al. Resistance of Neisseria gonorrhoeae to
 655 antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system.
 656 *Microbiology (Reading).* 1995;141 (Pt 3):611-22.
- 657 7. Lucas CE, Balthazar JT, Hagman KE, et al. The MtrR repressor binds the DNA sequence
 658 between the mtrR and mtrC genes of Neisseria gonorrhoeae. *J Bacteriol.*659 1997;179(13):4123-8.
- 8. Warner DM, Shafer WM, and Jerse AE. Clinically relevant mutations that cause
 derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer
 different levels of antimicrobial resistance and in vivo fitness. *Mol Microbiol.*2008;70(2):462-78.
- 664 9. Lyu M, Ayala JC, Chirakos I, et al. Structural Basis of Peptide-Based Antimicrobial
 665 Inhibition of a Resistance-Nodulation-Cell Division Multidrug Efflux Pump. *Microbiol*666 Spectr. 2022;10(5):e0299022.
- 10. Delahay RM, Robertson BD, Balthazar JT, et al. Involvement of the gonococcal MtrE
 protein in the resistance of Neisseria gonorrhoeae to toxic hydrophobic agents. *Microbiology (Reading).* 1997;143 (Pt 7):2127-33.
- Handing JW, Ragland SA, Bharathan UV, et al. The MtrCDE Efflux Pump Contributes
 to Survival of Neisseria gonorrhoeae From Human Neutrophils and Their Antimicrobial
 Components. *Front Microbiol.* 2018;9:2688.
- Hagman KE, and Shafer WM. Transcriptional control of the mtr efflux system of
 Neisseria gonorrhoeae. *J Bacteriol.* 1995;177(14):4162-5.
- Shafer WM, Balthazar JT, Hagman KE, et al. Missense mutations that alter the DNAbinding domain of the MtrR protein occur frequently in rectal isolates of Neisseria
 gonorrhoeae that are resistant to faecal lipids. *Microbiology (Reading)*. 1995;141 (Pt
 4):907-11.
- I4. Janganan TK, Zhang L, Bavro VN, et al. Opening of the outer membrane protein channel
 in tripartite efflux pumps is induced by interaction with the membrane fusion partner. J *Biol Chem.* 2011;286(7):5484-93.
- Bolla JR, Su CC, Do SV, et al. Crystal structure of the Neisseria gonorrhoeae MtrD inner
 membrane multidrug efflux pump. *PLoS One*. 2014;9(6):e97903.

684 16. Hoffmann KM, Williams D, Shafer WM, et al. Characterization of the multiple 685 transferable resistance repressor, MtrR, from Neisseria gonorrhoeae. J Bacteriol. 686 2005;187(14):5008-12. 687 17. Zalucki YM, Dhulipala V, and Shafer WM. Dueling regulatory properties of a 688 transcriptional activator (MtrA) and repressor (MtrR) that control efflux pump gene 689 expression in Neisseria gonorrhoeae. mBio. 2012;3(6):e00446-12. 690 18. Rouquette C, Harmon JB, and Shafer WM. Induction of the mtrCDE-encoded efflux 691 pump system of Neisseria gonorrhoeae requires MtrA, an AraC-like protein. Mol 692 Microbiol. 1999:33(3):651-8. 693 19. Jerse AE, Sharma ND, Simms AN, et al. A gonococcal efflux pump system enhances 694 bacterial survival in a female mouse model of genital tract infection. Infect Immun. 695 2003;71(10):5576-82. 696 20. Rouquette-Loughlin CE, Reimche JL, Balthazar JT, et al. Mechanistic Basis for 697 Decreased Antimicrobial Susceptibility in a Clinical Isolate of Neisseria gonorrhoeae 698 Possessing a Mosaic-Like mtr Efflux Pump Locus. mBio. 2018;9(6). 699 21. Veal WL, Yellen A, Balthazar JT, et al. Loss-of-function mutations in the mtr efflux 700 system of Neisseria gonorrhoeae. Microbiology (Reading). 1998;144 (Pt 3):621-7. 701 Veal WL, Nicholas RA, and Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux 22. 702 pump due to an mtrR mutation is required for chromosomally mediated penicillin 703 resistance in Neisseria gonorrhoeae. J Bacteriol. 2002;184(20):5619-24. 704 23. Ohneck EA, Zalucki YM, Johnson PJ, et al. A novel mechanism of high-level, broad-705 spectrum antibiotic resistance caused by a single base pair change in Neisseria 706 gonorrhoeae. mBio. 2011;2(5). 707 Warner DM, Folster JP, Shafer WM, et al. Regulation of the MtrC-MtrD-MtrE efflux-24. 708 pump system modulates the in vivo fitness of Neisseria gonorrhoeae. J Infect Dis. 709 2007;196(12):1804-12. 710 Golparian D, Shafer WM, Ohnishi M, et al. Importance of multidrug efflux pumps in the 25. 711 antimicrobial resistance property of clinical multidrug-resistant isolates of Neisseria 712 gonorrhoeae. Antimicrob Agents Chemother. 2014;58(6):3556-9. 713 Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era 26. 714 of untreatable gonorrhea?: detailed characterization of the first strain with high-level 715 resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538-45. 716 27. Hobbs MM, Sparling PF, Cohen MS, et al. Experimental Gonococcal Infection in Male 717 Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and 718 MS11mkC. Front Microbiol. 2011;2:123. 719 28. Waltmann A DJ, Pier GB, Cywes-Bentley C, Cohen MC, Hobbs MM. In: Fabio Bagnoli 720 GDG, Sanjay K. Phogat, Rino Rappuoli ed. Human Challenge Studies for Vaccine 721 Development. Springer Nature; 2021. 722 Hobbs MM, Anderson JE, Balthazar JT, et al. Lipid A's structure mediates Neisseria 29. 723 gonorrhoeae fitness during experimental infection of mice and men. mBio. 724 2013;4(6):e00892-13. 725 Jerse AE. Experimental gonococcal genital tract infection and opacity protein expression 30. 726 in estradiol-treated mice. Infect Immun. 1999;67(11):5699-708. 727 31. Feinen B, Jerse AE, Gaffen SL, et al. Critical role of Th17 responses in a murine model 728 of Neisseria gonorrhoeae genital infection. Mucosal Immunol. 2010;3(3):312-21.

729	32.	Jerse AE, Wu H, Packiam M, et al. Estradiol-Treated Female Mice as Surrogate Hosts for
730		Neisseria gonorrhoeae Genital Tract Infections. Front Microbiol. 2011;2:107.
731	33.	Jerse AE, Crow ET, Bordner AN, et al. Growth of Neisseria gonorrhoeae in the female
732		mouse genital tract does not require the gonococcal transferrin or hemoglobin receptors
733		and may be enhanced by commensal lactobacilli. <i>Infect Immun</i> . 2002;70(5):2549-58.
734	34.	Soler-Garcia AA, and Jerse AE. Neisseria gonorrhoeae catalase is not required for
735	0.11	experimental genital tract infection despite the induction of a localized neutrophil
736		response. Infect Immun 2007:75(5):2225-33.
737	35	Muench DF Kuch DI Wu H et al Hydrogen peroxide-producing lactobacilli inhibit
738	55.	gonococci in vitro but not during experimental genital tract infection
739		2009·199(9)·1369-78
740	36	Song W Condron S Mocca BT et al Local and humoral immune responses against
741	50.	primary and repeat Neisseria gonorrhoeae genital tract infections of 17beta-estradiol-
742		treated mice Vaccine 2008.26(45):5741-51
743	37	Leduc I Connolly KI Begum A et al The serogroup B meningococcal outer membrane
743	57.	vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria
745		gonorrhoese PLoS Pathog 2020:16(12):e1008602
746	38	Ma KC Mortimer TD Hicks AI et al Adaptation to the cervical environment is
740	50.	associated with increased antibiotic suscentibility in Neisseria gonorrhoeae Nat
748		Commun 2020:11(1):4126
749	39	Nachamkin I. Cannon IG and Mittler RS. Monoclonal antibodies against Neisseria
750	57.	gonorrhoeae: production of antibodies directed against a strain-specific cell surface
751		antigen Infact Immun 1981:32(2):641-8
752	40.	Lyu M. Moseng MA. Reimche II., et al. Cryo-EM Structures of a Gonococcal Multidrug
753		Efflux Pump Illuminate a Mechanism of Drug Recognition and Resistance. <i>mBio</i>
754		2020:11(3).
755	41.	Barnes PD, Bergman MA, Mecsas J, et al. Yersinia pseudotuberculosis disseminates
756		directly from a replicating bacterial pool in the intestine. J Exp Med. 2006:203(6):1591-
757		601.
758	42.	Brown SP, Cornell SJ, Sheppard M, et al. Intracellular demography and the dynamics of
759		Salmonella enterica infections. <i>PLoS Biol.</i> 2006;4(11):e349.
760	43.	Gerlini A, Colomba L, Furi L, et al. The role of host and microbial factors in the
761		pathogenesis of pneumococcal bacteraemia arising from a single bacterial cell bottleneck.
762		<i>PLoS Pathog.</i> 2014;10(3):e1004026.
763	44.	Grant AJ, Restif O, McKinley TJ, et al. Modelling within-host spatiotemporal dynamics
764		of invasive bacterial disease. <i>PLoS Biol.</i> 2008:6(4):e74.
765	45.	Moxon ER, and Murphy PA. Haemophilus influenzae bacteremia and meningitis
766		resulting from survival of a single organism. Proc Natl Acad Sci USA. 1978;75(3):1534-
767		6.
768	46.	Sheppard M, Webb C, Heath F, et al. Dynamics of bacterial growth and distribution
769		within the liver during Salmonella infection. <i>Cell Microbiol.</i> 2003;5(9):593-600.
770	47.	Joseph SB, Swanstrom R, Kashuba AD, et al. Bottlenecks in HIV-1 transmission:
771		insights from the study of founder viruses. Nat Rev Microbiol. 2015;13(7):414-25.
772	48.	Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of
773		transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl
774		Acad Sci U S A. 2008;105(21):7552-7.

- 49. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralizationsensitive HIV-1 after heterosexual transmission. *Science*. 2004;303(5666):2019-22.
- 50. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection
 with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution
 of transmitted variants. *J Virol.* 2009;83(8):3556-67.
- 51. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections
 mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C
 HIV-1. *PLoS Pathog.* 2009;5(1):e1000274.
- 52. Lovett A, and Duncan JA. Human Immune Responses and the Natural History of
 Neisseria gonorrhoeae Infection. *Front Immunol.* 2018;9:3187.
- 53. Ercoli G, Fernandes VE, Chung WY, et al. Intracellular replication of Streptococcus
 pneumoniae inside splenic macrophages serves as a reservoir for septicaemia. *Nat Microbiol.* 2018;3(5):600-10.
- 54. Kono M, Zafar MA, Zuniga M, et al. Single Cell Bottlenecks in the Pathogenesis of
 Streptococcus pneumoniae. *PLoS Pathog.* 2016;12(10):e1005887.
- 790 55. Zafar MA, Kono M, Wang Y, et al. Infant Mouse Model for the Study of Shedding and
 791 Transmission during Streptococcus pneumoniae Monoinfection. *Infect Immun.* 792 2016;84(9):2714-22.
- 56. Liu X, Kimmey JM, Matarazzo L, et al. Exploration of Bacterial Bottlenecks and
 Streptococcus pneumoniae Pathogenesis by CRISPRi-Seq. *Cell Host Microbe*.
 2021;29(1):107-20 e6.
- Find Strain Find Strain Stra
- 79958.Marjuki H, Topaz N, Joseph SJ, et al. Genetic Similarity of Gonococcal Homologs to800Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. *mBio*. 2019;10(5).
- 801 59. Perrin A, Bonacorsi S, Carbonnelle E, et al. Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. *Infect Immun.* 2002;70(12):7063-72.
- Tinsley CR, and Nassif X. Analysis of the genetic differences between Neisseria
 meningitidis and Neisseria gonorrhoeae: two closely related bacteria expressing two
 different pathogenicities. *Proc Natl Acad Sci U S A*. 1996;93(20):11109-14.
- Bayliss CD, Hoe JC, Makepeace K, et al. Neisseria meningitidis escape from the
 bactericidal activity of a monoclonal antibody is mediated by phase variation of lgtG and
 enhanced by a mutator phenotype. *Infect Immun.* 2008;76(11):5038-48.
- 810 62. Banerjee A, Wang R, Uljon SN, et al. Identification of the gene (lgtG) encoding the
 811 lipooligosaccharide beta chain synthesizing glucosyl transferase from Neisseria
 812 gonorrhoeae. *Proc Natl Acad Sci U S A*. 1998;95(18):10872-7.
- 813 63. Shafer WM, Datta A, Kolli VS, et al. Phase variable changes in genes lgtA and lgtC
 814 within the lgtABCDE operon of Neisseria gonorrhoeae can modulate gonococcal
 815 susceptibility to normal human serum. *J Endotoxin Res.* 2002;8(1):47-58.
- 64. Gulati S, Zheng B, Reed GW, et al. Immunization against a saccharide epitope
 accelerates clearance of experimental gonococcal infection. *PLoS Pathog.*2013;9(8):e1003559.
- 65. Gulati S, Beurskens FJ, de Kreuk BJ, et al. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. *PLoS Biol.* 2019;17(6):e3000323.

821	66.	Golubchik T, Batty EM, Miller RR, et al. Within-host evolution of Staphylococcus
822		aureus during asymptomatic carriage. PLoS One. 2013;8(5):e61319.
823	67.	Jerse AE, Cohen MS, Drown PM, et al. Multiple gonococcal opacity proteins are
824		expressed during experimental urethral infection in the male. J Exp Med.
825		1994;179(3):911-20.
826	68.	Seifert HS, Wright CJ, Jerse AE, et al. Multiple gonococcal pilin antigenic variants are
827		produced during experimental human infections. J Clin Invest. 1994;93(6):2744-9.
828	69.	Wright CJ, Jerse AE, Cohen MS, et al. Nonrepresentative PCR amplification of variable
829		gene sequences in clinical specimens containing dilute, complex mixtures of
830		microorganisms. J Clin Microbiol. 1994;32(2):464-8.
831	70.	Hamrick TS, Dempsey JAF, Cohen MS, et al. Antigenic variation of gonococcal pilin
832		expression in vivo: analysis of the strain FA1090 pilin repertoire and identification of the
833		pilS gene copies recombining with pilE during experimental human infection.
834		Microbiology (Reading). 2001;147(Pt 4):839-49.
835	71.	Gor V, Ohniwa RL, and Morikawa K. No Change, No Life? What We Know about Phase
836		Variation in Staphylococcus aureus. <i>Microorganisms</i> . 2021;9(2).
837	72.	Aidley J, Rajopadhye S, Akinyemi NM, et al. Nonselective Bottlenecks Control the
838		Divergence and Diversification of Phase-Variable Bacterial Populations. mBio.
839		2017;8(2).
840	73.	Libby E, and Rainey PB. Exclusion rules, bottlenecks and the evolution of stochastic
841		phenotype switching. Proc Biol Sci. 2011;278(1724):3574-83.
842	74.	Palmer ME, Lipsitch M, Moxon ER, et al. Broad conditions favor the evolution of phase-
843		variable loci. <i>mBio</i> . 2013;4(1):e00430-12.
844	75.	Moxon R, and Kussell E. The impact of bottlenecks on microbial survival, adaptation,
845		and phenotypic switching in host-pathogen interactions. <i>Evolution</i> . 2017;71(12):2803-16.
846	76.	Abraham SN, and Miao Y. The nature of immune responses to urinary tract infections.
847		<i>Nat Rev Immunol.</i> 2015;15(10):655-63.
848	77.	Pudney J, and Anderson D. Innate and acquired immunity in the human penile urethra. J
849		<i>Reprod Immunol.</i> 2011;88(2):219-27.
850	78.	Abel S, Abel zur Wiesch P, Davis BM, et al. Analysis of Bottlenecks in Experimental
851		Models of Infection. <i>PLoS Pathog</i> . 2015;11(6):e1004823.
852	79.	Qu J, Prasad NK, Yu MA, et al. Modulating Pathogenesis with Mobile-CRISPRi. J
853		<i>Bacteriol</i> . 2019;201(22).
854	80.	Garvin LE, Bash MC, Keys C, et al. Phenotypic and genotypic analyses of Neisseria
855		gonorrhoeae isolates that express frequently recovered PorB PIA variable region types
856		suggest that certain P1a porin sequences confer a selective advantage for urogenital tract
857		infection. <i>Infect Immun</i> . 2008;76(8):3700-9.
858	81.	Johnston DM, and Cannon JG. Construction of mutant strains of Neisseria gonorrhoeae
859		lacking new antibiotic resistance markers using a two gene cassette with positive and
860		negative selection. Gene. 1999;236(1):179-84.
861	82.	Cohen MS, Cannon JG, Jerse AE, et al. Human experimentation with Neisseria
862		gonorrhoeae: rationale, methods, and implications for the biology of infection and
863		vaccine development. J Infect Dis. 1994;169(3):532-7.
864	83.	Cornelissen CN, Kelley M, Hobbs MM, et al. The transferrin receptor expressed by
865		gonococcal strain FA1090 is required for the experimental infection of human male
866		volunteers. Mol Microbiol. 1998;27(3):611-6.

- 867 84. Raterman EL, and Jerse AE. Female Mouse Model of Neisseria gonorrhoeae Infection.
 868 *Methods Mol Biol.* 2019;1997:413-29.
- 869 85. Dillard JP. Genetic Manipulation of Neisseria gonorrhoeae. *Curr Protoc Microbiol.*870 2011;Chapter 4:Unit4A 2.
- 86. Mickelsen PA, and Sparling PF. Ability of Neisseria gonorrhoeae, Neisseria meningitidis,
 and commensal Neisseria species to obtain iron from transferrin and iron compounds. *Infect Immun.* 1981;33(2):555-64.